<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hypoplastic <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (HAL) is characterized by <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> and by hypocellularity of the bone marrow </plain></SENT>
<SENT sid="1" pm="."><plain>The marrow contains equal to or more than 30% myeloblasts </plain></SENT>
<SENT sid="2" pm="."><plain>Absence of tissue infiltrates and/or <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> masses is mandatory </plain></SENT>
<SENT sid="3" pm="."><plain>Eight patients are described here </plain></SENT>
<SENT sid="4" pm="."><plain>They do not fit into the FAB classification for either <z:hpo ids='HP_0011009'>acute</z:hpo> nonlymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (ANLL) or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), except for one patient who subsequently proved to have a <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>The median age is 65 years </plain></SENT>
<SENT sid="6" pm="."><plain>Two patients, including the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> patient, are alive, 22 and 6 months from diagnosis </plain></SENT>
<SENT sid="7" pm="."><plain>Six patients have died </plain></SENT>
<SENT sid="8" pm="."><plain>The median survival is 8 months </plain></SENT>
<SENT sid="9" pm="."><plain><z:mpath ids='MPATH_458'>Normal</z:mpath> bone marrow cells cultured either with HAL sera or with HAL peripheral blood mononuclear cells as feeders and exogenous GM-CSF yielded subnormal CFU-GM counts </plain></SENT>
<SENT sid="10" pm="."><plain>This might indicate inhibitory activity of HAL serum and defective stimulatory activity of HAL peripheral blood mononuclear cells </plain></SENT>
</text></document>